Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel

• DOI: 10.1007/s11239-016-1460-2
• Publication Date: 2016-12-15T08:10:47Z
• Authors: Takahisa Furuta; Mitsushige Sugimoto; Chise Kodaira; Masafumi Nishino; Mihoko Yamade; Takahiro Uotani; Shu Sahara; Hitomi Ichikawa; Takuma Kagami; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Ken Sugimoto; Kazuo Umemura
• Keywords: Adult; Male; Ticlopidine; Time Factors; Platelet Aggregation; Proton Pump Inhibitors; Healthy Volunteers; Clopidogrel; 3. Good health; Cytochrome P-450 CYP2C19; 03 medical and health sciences; 0302 clinical medicine; Japan; Rabeprazole; Humans; Drug Interactions; Drug Therapy, Combination; Female; Platelet Aggregation Inhibitors

Proton pump inhibitors (PPIs) at low doses can effectively prevent gastrointestinal bleeding due to aspirin and are widely used in Japan for gastroprotection in patients taking anti-platelet agents. We examined the influence of different PPIs at low doses administered concomitantly or separately on anti-platelet functions of clopidogrel. In 41 healthy Japanese volunteers with different CYP2C19 genotypes who took clopidogrel 75 mg in the morning alone, or with omeprazole 10 mg, esomeprazole 10 mg, lansoprazole 15 mg, or rabeprazole 10 mg, either concomitantly in the morning or separately in the evening, we measured the inhibition of platelet aggregation (IPA, %) using VerifyNow P2Y12 assay at 4 h after the last clopidogrel dose on Day 7 of each regimen. IPA by clopidogrel with rabeprazole administered at lunchtime, approximately 4 h after clopidogrel, was also measured. Mean IPAs in those concomitantly receiving omeprazole, esomeprazole, lansoprazole or rabeprazole (47.2 ± 21.1%, 43.2 ± 20.2%, 46.4 ± 18.8%, and 47.3 ± 19.2%, respectively) were significantly decreased compared with those receiving clopidogrel alone (56.0%) (all ps < 0.001). This decrease was observed when PPIs were administered separately in the evening. However, IPA by clopidogrel with rabeprazole administered at lunchtime was 51.6%, which was markedly similar to that of clopidogrel alone (p = 0.114). All tested PPIs reduce the efficacy of clopidogrel when administered concomitantly. Our preliminary data suggest that administration of rabeprazole 4 h following clopidogrel may minimize potential drug-drug interactions.